Available Technology

Broadly Neutralizing Anti-HIV Monoclonal Antibody That Targets a New Epitope on gp41

Blocking entry of HIV into cells and vaccine development against HIV are the prime targets of HIV therapy and prevention, respectively. Current invention describes a monoclonal Fab anti-HIV antibody isolated through panning against the chimeric construct NCCG-gp41 by Antibodies-by-Design (Morphosys). One of the antibodies has broadly neutralization ability against several HIV subtypes in an envelope-pseudotyped-virus neutralization assay. This antibody was also shown to have synergistic effect with a gp41-derived peptide discovered in this laboratory in inhibiting HIV-1 fusion.
Patent Abstract: 
Blocking entry of HIV into cells and vaccine development against HIV are the prime targets of HIV therapy and prevention, respectively. Current invention describes a monoclonal Fab anti-HIV antibody isolated through panning against the chimeric construct NCCG-gp41 by Antibodies-by-Design (Morphosys). One of the antibodies has broadly neutralization ability against several HIV subtypes in an envelope-pseudotyped-virus neutralization assay. This antibody was also shown to have synergistic effect with a gp41-derived peptide discovered in this laboratory in inhibiting HIV-1 fusion.
Benefits 
Can be potentially used as a therapeutic agent to block HIV-1 entry into cells.
applications 
Inventors: 
G. Marius Clore
Internal Laboratory Ref #: 
E-229-2008/0
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin